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Solubleextracellular fragments ofreceptorsmay serve as naturalblockers oftheir
respective hormones or cytokines. Only a limited number ofsuch soluble receptor
fragments were reported, including receptors for RBCs (1) and for the Fc portion
of Igs (2). Among the cytokine receptors, IL-2-R was the only one reported to be
released in a soluble form from activated human lymphoid cells (3). Moreover, it
was detected in body fluids of normal individuals and its level was increased in dis-
easestates (4). Toaddressthe question ofwhetherrelease ofsoluble cytokine receptors
into body fluids is a general phenomenon, we analyzed urine ofnormal donors for
thepresence ofadditional cytokine receptors. Affinity chromatography ofcrude human
urinaryproteins oneither immobilized human rIL-6, immobilizedhuman rIFN-y,
or immobilized anti-IFN-y-R mAb yielded the two respective soluble receptors in
significant quantities. It is therefore suggested that shedding of various cytokine
receptors is a general phenomenon that occurs undernormal physiologicalconditions.
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Materials and Methods
BriefDefinitive Report
Cytokines.
￿
rIL-6 and rIFN-y (provided by InterPharm laboratories, Ness-Ziona, Israel)
were purified to homogeneity on an anti-IL-6 mAb column (5) and an IFN-y mAb column
(6), respectively. Iodination of cytokines was performed by the chloramineT method to a
specific activity of 2.2 x 107 cpm/14g for rIL-6 and 2.5 x 106 cpm/Ag for rIFN-y.
Antibodies.
￿
mAb 34-1 (5) was used. for affinity purification of IL-6. mAb 3-3 (7) was used
both for affinity purification of rIFN-y and for coating microtiter plates in a solid phase RIA
(sRIA). mAb 177-1 (8) was used both for immunoaffinity purification of the IFN-y-R from
crudeurine and for coating microtiter plates in a double-antibody ELISA. Rabbit anti-IFN-
y-R polyclonal antibodies were obtained by immunization with a ligand affinity-purified IFN-
y-R from human placenta.
LigandAffinity Chromatography of Urine.
￿
Each ofthe cytokines (2.5 mg) was coupled to Affigel-
10 (1 ml; Bio-Rad Laboratories, Richmond, CA). Concentrated crude or partially purified
urinary proteins (9) were passed on each of the columns. After washings with PBS, bound
proteins were eluted by citric acid (25 mM; pH 2.5) and immediately neutralized.
Reversed Phase HPLC
￿
Eluted fractions from the immobilized IL-6 column were further
resolved by reversed-phase (rp)HPLC (Aquapore RP-300, 4.6 x 30 mm; Brownlee Labs.,
SantaClara, CA) using an acetonitrile gradient in 0.3% aqueaus trifluoroacetic acid (TFA).
0.5-ml fractions were collected.
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SDS-PAGE andElectroblotting
￿
Proteins resolved by SDS-PAGE (1250 acrylamide) under
nonreducing conditions (10) were visualized either by silver staining (11) or electroblotted
on nitrocellulose sheets as previously described (8). Electroblotted proteins were reacted ei-
ther with 1251-rIL-6 (106 cpm/ml) or with mAb 177-1 (1 :500), followed by 1251-goat anti-mouse
antibodies (0.7 x 106 cpm/ml). The nitrocellulose sheets were then washed, dried, and au-
toradiographed.
Inhibition ofIFN--y Binding to its mAb in sRIA.
￿
PVC plates coated with anti-IFN-y mAb
3-3 and blocked with BSA were incubated with 125I-IFN-y (104 cpm/well) in the presence or
absence ofaffinity-purified urinary proteins. The wells were then washed, cut, and counted.
Double Antibody ELISA.
￿
96-well ELISA plates coated with anti-IFN-y-R mAb 177-1 and
blocked with BSA were incubated first with affinity-purified urinary proteins, then with rabbit
anti-IFN-y-R serum (1 :1,000), and then with goat anti-rabbit antibody conjugated to horse-
radish peroxidase (Sigma Chemical Co., St. Louis, MO). The plates were then washed and
incubated with a peroxidase substrate (ABTS; Sigma Chemical Co.) and measured by an
ELISA reader.
ProteinDetermination.
￿
Protein concentrations were determinedby the fluorescamine method
(12).
NH2-terminal Sequence Analysis.
￿
The HPLC-purified protein was subjected to NH2-termi-
nal sequence analysis on a pulsed liquid gas phase protein microsequencer (475A; Applied
Biosystems, Inc., Foster City, CA).
Results
Affinity chromatography on an immobilized rIL-6 column was used as the main
step of IL-6-R purification. A concentrate of crude urinary proteins (1 .5 g protein
in 100 ml obtained from 40 liters ofurine) was passed on the IL-6 column, and bound
proteins (50 hg) were eluted by low pH. Further purification was achieved by RP-
HPLC, which yielded a major protein peak (14 Ag) (Fig. 1, fr. 42). On scale up of
these procedures, 110 ug ofpure protein was obtained from CM-Sepharose-purified
urinary proteins (9), starting with 900 liters of urine. Analysis by SDS-PAGE of
the protein peak from the RP-HPLC column gave a single broad band of Mr 5 x
104 t 104 under nonreducing conditions. After electroblotting of the partially
1
￿
.
￿
1
0 20 40 60 80
Frocfion number
FIGURE 1.
￿
Purification of the urinary IL-6-R
by RP-HPLC. Ligand (IL-6) affinity-purified uri-
nary proteins were applied to the HPLC column,
eluted at 0.5 ml/min by an acetonitrile gradient
(dotted line), and the protein was monitored by a
preparative fluorescamine system (12) (solidline).
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purified protein sample from the affinity column eluate, only the -5 x 104 t 104
band reacted specifically with 1251-IL-6 (Fig. 2) . The protein peak from the RP-
HPLC was further characterized by NH2-terminal microsequencing and a single
sequence of30 amino acid residues was obtained : L A P R R (C) P AQEV A
R GV L T S L P G D S V T L T(C) PG. This sequence was identical to the
predicted NH2-terminal sequence of IL-6-R as previously reported (13) ; cysteine
(C) is not detectable in the protein microsequencer . TheNH2 terminus of this nat-
ural receptor fragment confirms the presumed cleavage point of the signal peptide
oftheprimary translation product (13) . The apparent molecular weight of this frag-
ment may correspond to the extracellular portion of mature IL-6-R .
We then searched for the possible existence of soluble IFN-y-R or other IFN-'y
bindingproteins. Two approaches were attempted . In the first, ligand affinity chro-
matography was used, while in thesecond, immunoaffinity chromatography wasused .
Application of crude proteins from 125 liters of urine on the rIFN-'y column (14)
andelution at lowpH yielded 3714gof IFN--y binding proteins . Applicationofcrude
proteins from 100 liters of urine on an immobilized anti-IFN-y-R mAb 177-1 (8)
andelution at lowpH yielded 70 wg of proteins . Analysis of the eluted proteins from
both columns by SDS-PAGE, under nonreducing conditions, followed by silver
staining, revealed a similar pattern of protein bands, corresponding to proteins of
M,4 x 104 , 5.3 x 104 , and two protein bands >9.3 x 104 (Fig. 3, lanes 2 and 3) .
After electroblottingonto nitrocellulose membrane, only the 40-kD protein in both
preparations reacted specifically with the anti-IFN-y-R mAb (Fig. 3, lanes 4 and
5) . The same band also reacted specifically with "5I-IFN-'v, but the signal was faint
(data not shown) . From the results obtained it was concluded that 40-kD protein
is the ligand binding domain of the IFN-y-R . Further confirmation of the identity
of the IFN-y binding protein as IFN-y-R was obtained by two additional tests . The
eluate of the rIFN-y column inhibited, in a dose-dependent manner, the binding
of 1251-IFN-y to anti-IFN-y mAb 3-3 in an sRIA (Fig . 4 a) . The same eluate gave
a specific signal in a double-antibody ELISA based on monoclonal and polyclonal
anti-IFN-y-R antibodies (Fig. 4 b) .
FIGURE 2 .
￿
Analysis of the purified IL-6-R by SDS-PAGE and by
1251-rIL-6 binding. Silver-stained SDS-PAGE: lane 1, molecular mass
(kD) markers ; lane 2, aliquot (850 ng) ofHPLC fraction 42 (Fig . 1) .
Autoradiograph of 1251-rIL-6 bound to electroblotted proteins: lane
3, ligand (IL-6) affinity-purified . urinary proteins (1 .8 Wg) ; lane 4, ligand
(IFN-- f) affinity-purified urinary proteins (1.5 hg, negative control) .1412
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FIGURE 3 .
￿
AnalysisofIFN-y binding
proteins by SDS-PAGEandbyWestern
blotting. Silver-stained SDS-PAGE:
lane 1, molecular mass (kD) markers ;
lane 2, ligand (IFN-y) affinity-purified
urinary proteins (300 ng) ; lane 3, im-
munoaffinity (anti-IFN-y-R mAb)-
purified urinary proteins (250 ng) .
Autoradiograph of a Western blot
performed with anti-IFN-y-R mAb :
lane 4, ligand (IFN-y) affinity-purified
urinary proteins (600 ng); lane 5, im-
munoafftnity (anti-IFN-y-R mAb)-
purified urinary proteins (900 ng); lane
6, ligand (IL-6) affinity-purified uri-
nary proteins (1,200 ng, negative con-
trol) ; lane 7, IaC molecular mass (kD)
markers .
FIGURE 4 . (a) Inhibition of 125I-rIFN-y binding in sRIA by
ligand IFN-y) affinity-purified urinary proteins.Maximal binding
with 12 I-rIFN-y alone was 4,300 cpm . Background binding (200
cpm) was determined in the presence of excess unlabeled rIFN-y
andwas subtracted from all readings. Immunoaffinity-purified IFN-
y-Rfrom human placenta (8) (8 pg/ml) wasused as a positive con-
trol and gave 80% inhibition . Ligand (IL-6) affinity-purified uri-
nary protein (10 jig/ml)was used as a negative control and gave
only 10% inhibition . (b) Characterization of IFN-y binding pro-
teins as receptors by adouble-antibodyELISA. Immunoaffinity-
purified IFN-y-R from human placenta (8) (0.5 Kg/ml) wasused
as a positive control and gave 0.45OD6oo . Ligand (IL-6) affinity-
purified urinary proteins (0.5 Wg/ml) were used as a negative con-
trol and gave 0.06 OD6w .
Discussion
Thepresent study proves the existence ofspecific receptors forthe IL-6 and IFN-,y
cytokines in normal human urine . This finding, together with the already known
presence ofsoluble IL-2-R in both plasma andurine, indicates that releaseofsoluble
cytokine receptors into body fluids isageneral phenomenon that occurs undernormal
physiological conditions . We recently found that aurinary protein that inhibitsTNF
activity (15), shown by us and others to function by binding TNF specifically (9,
16), also represents a soluble version of a cell surface TNF receptor (Engelmann,H ., D. Novick, and D. Wallach, manuscript submitted for publication). Soluble
receptors can be derived either by shedding of cell surface receptors or by a separate
biosynthetic pathway starting from alternatively spliced mRNA or even from a dis-
tinct gene. However, the protein sequence identity of the soluble part of the IL-6-R
described by us and the reported IL-6-R cDNA indicates that both proteins are de-
rived from the same gene. The observed prevalence of soluble cytokine receptors
suggests that they may have an immunoregulatory role, either by participation in
the process of eliminating cytokines via the kidney or, if present in the plasma, as
shown for IL-2-R, by modulating the availability of their corresponding cytokines.
Summary
Affinity chromatography ofcrude human urinary proteins on either human rIL-6,
human rIFN-y, or anti-IFN-y-R mAb yielded the two respective soluble receptors
in significant quantities. A single sequence of 30 amino acid residues was obtained
by NH2-terminal microsequencing of the protein peak purified in tandem by affinity
chromatography on an IL-6 column and reversed-phase HPLC. This sequence was
identical to the predicted N112-terminal sequence of IL-6-R as previously reported.
Analysis ofthe eluted proteins from both IFN-y and anti-IFN-y-R columns by inhi-
bition of solid phase RIA, ELISA, SDS-PAGE, and Western blotting proved the
existence of soluble IFN-y-R in normal urine. Our finding, together with the al-
ready known presence ofurinary TNF binding proteins and a soluble IL-2-R both
in plasma and in urine, indicates that release of soluble cytokine receptors into body
fluids is a general phenomenon that occurs under normal physiological conditions.
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